Acute Myeloid Leukemia Post Cytotoxic Therapy

Acute Myeloid Leukemia Post Cytotoxic Therapy — Trials · CancerIndex

Clinical trials

Registered studies

55 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 17
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 6%
Top sponsor: National Cancer Institute (NCI)
Termination share: 19.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (6)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01861314	Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia	active not recruiting	Phase 1	15	National Cancer Institute (NCI)NIH	1	Sep 11, 2026	clinicaltrials
NCT05146739	Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane	active not recruiting	Phase 1	8	National Cancer Institute (NCI)NIH